Biomarkers for Detecting Pancreatic Cancer
Pancreatic cancer is a highly lethal malignancy, primarily due to its late diagnosis and aggressive nature. The five-year survival rate remains low, often below 10%, as the disease is frequently detected at an advanced stage when surgical options are limited[1][5]. Therefore, the development of effective biomarkers for early detection is crucial to improving patient outcomes. Current Biomarkers The most widely used biomarker for pancreatic cancer is Carbohydrate Antigen 19-9 (CA19-9). Although it is approved by the FDA for monitoring treatment response and recurrence, its sensitivity and specificity are not sufficient for early-stage diagnosis[4][9]. CA19-9 is often elevated in other conditions, such as liver disease and pancreatitis, which limits its diagnostic utility[7]. Emerging Biomarkers Recent research has focused on identifying novel biomarkers that could improve early detection. These include: – Protein Biomarkers: Studies have identified proteins such as REG1A and REG1B…


